Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
04 1월 2024 - 11:40AM
Business Wire
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
the pricing of an upsized underwritten public offering of
10,000,000 shares of its voting common stock at a price to the
public of $21.00 per share. The gross proceeds to Longboard from
the offering, before deducting underwriting discounts and
commissions and estimated offering expenses, are expected to be
$210.0 million. In addition, Longboard has granted the underwriters
a 30-day option to purchase up to an additional 1,500,000 shares of
voting common stock at the public offering price, less underwriting
discounts and commissions. The offering is expected to close on
January 8, 2024, subject to satisfaction of customary closing
conditions.
Cantor and Citigroup are acting as joint lead book-running
managers for the offering, and Wedbush PacGrow and H.C. Wainwright
& Co. are acting as lead managers for the offering.
The offering is being made pursuant to two shelf registration
statements on Form S-3, including base prospectuses, which were
previously filed with the Securities and Exchange Commission (the
“SEC”) and declared effective on October 11, 2022 and August 11,
2023, respectively, as well as a related registration statement on
Form S-3MEF. A preliminary prospectus supplement and accompanying
prospectuses relating to the offering were filed with the SEC and
are available for free on the SEC’s website located at
http://www.sec.gov. A final prospectus supplement and accompanying
prospectuses relating to the offering will be filed with the SEC
and will be available for free on the SEC’s website located at
http://www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectuses relating to the offering, when
available, may be obtained from: Cantor Fitzgerald & Co.,
Attention: Capital Markets, 110 East 59th Street, New York, NY
10022, or by e-mail at prospectus@cantor.com; or Citigroup, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717 or by telephone at (800) 831-9146.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard plans to advance bexicaserin (LP352), an oral,
centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor
superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor
subtypes, into a global Phase 3 program. In January 2024, Longboard
reported topline data from a Phase 1b/2a clinical trial, the
PACIFIC Study, evaluating bexicaserin in participants ages 12 to 65
years old with a broad range of Developmental and Epileptic
Encephalopathies (DEEs), including Lennox-Gastaut syndrome, Dravet
syndrome and other DEEs. Longboard is also evaluating LP659, an
oral, centrally acting, sphingosine-1-phosphate (S1P) receptor
subtypes 1 and 5 modulator, which is in development for the
potential treatment of rare neuroinflammatory conditions. Longboard
has initiated a Phase 1 single-ascending dose (SAD) clinical trial
for LP659 in healthy volunteers, with topline data expected in the
first half of 2024.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, Longboard’s expectations regarding
the timing and completion of the offering, expected gross proceeds
from the offering and expected timing for topline data. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Words such as “expects,” “may,”
“will,” “potential” “focused on,” “working to,” “designed to,”
“plans to” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Longboard’s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with Longboard’s ongoing and planned
clinical trials and its business in general, macroeconomic events
stemming from evolving geopolitical developments such as the
conflicts in Ukraine and the Middle East and the other risks
described in Longboard’s filings with the SEC, including under the
heading “Risk Factors” contained therein, as well as the risks
identified in the registration statements and the preliminary
prospectus supplement relating to the proposed public offering. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management’s assumptions and estimates as of such date. Longboard
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103727932/en/
Corporate Contact: Megan E. Knight Head of Investor
Relations IR@longboardpharma.com 858.789.9283
Longboard Pharmaceuticals (NASDAQ:LBPH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024